Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in

Celyad Oncology SA
XBRU:CYAD

Watchlist Manager
Celyad Oncology SA Logo
Celyad Oncology SA
XBRU:CYAD
Watchlist
Price: 0.17 EUR -2.86% Market Closed
Market Cap: €7.6m
Write Note Create Alert Ask AI

Relative Value

The Relative Value of one CYAD stock under the Base Case scenario is hidden EUR. Compared to the current market price of 0.17 EUR, Celyad Oncology SA is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CYAD Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

P/S
View Details
P/E
View Details
P/OCF
View Details
P/FCFE
View Details
P/B
View Details
EV/S
View Details
EV/GP
View Details
EV/EBITDA
View Details
EV/EBIT
View Details
EV/OCF
View Details
EV/FCFF
View Details
EV/IC
View Details

Multiples Across Competitors

CYAD Competitors Multiples
Celyad Oncology SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
BE
Celyad Oncology SA
XBRU:CYAD
7m EUR 37.9 -1.1 -1.2 -1.1
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 643 258.8 -159 901.4 -194 171.3 -191 955.6
US
Abbvie Inc
NYSE:ABBV
397.7B USD 6.7 171.2 16.6 23.5
US
Amgen Inc
NASDAQ:AMGN
182.7B USD 5.1 26.2 18.8 18.8
US
Gilead Sciences Inc
NASDAQ:GILD
179.8B USD 6.2 22.2 15.1 15.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117.6B USD 10.1 32.2 23.6 24.7
US
Epizyme Inc
F:EPE
94.1B EUR 2 094 -534.3 -581.8 -566.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.5B USD 5.6 17.8 15.1 17.2
AU
CSL Ltd
ASX:CSL
86.7B AUD 3.9 20.1 13.4 16.8
NL
argenx SE
XBRU:ARGX
43.5B EUR 14.5 34.2 58.4 60.1
US
Seagen Inc
F:SGT
39.3B EUR 20.2 -61.8 -66.7 -60.2
P/S Multiple
Revenue Growth P/S to Growth
BE
Celyad Oncology SA
XBRU:CYAD
Average P/S: 3 058 678.5
37.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 643 258.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.7
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
5.1
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
6.2
4%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.1
10%
1
US
E
Epizyme Inc
F:EPE
2 094
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
8%
0.7
AU
CSL Ltd
ASX:CSL
3.9
5%
0.8
NL
argenx SE
XBRU:ARGX
14.5
49%
0.3
US
S
Seagen Inc
F:SGT
20.2
30%
0.7
P/E Multiple
Earnings Growth PEG
BE
Celyad Oncology SA
XBRU:CYAD
Average P/E: 46.3
Negative Multiple: -1.1 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -159 901.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
171.2
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
26.2
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
22.2
191%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
32.2
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -534.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
9%
2
AU
CSL Ltd
ASX:CSL
20.1
11%
1.8
NL
argenx SE
XBRU:ARGX
34.2
42%
0.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
BE
Celyad Oncology SA
XBRU:CYAD
Average EV/EBITDA: 23
Negative Multiple: -1.2 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 171.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.6
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.8
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
15.1
7%
2.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.6
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.1
24%
0.6
AU
CSL Ltd
ASX:CSL
13.4
8%
1.7
NL
argenx SE
XBRU:ARGX
58.4
810%
0.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.7 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
BE
Celyad Oncology SA
XBRU:CYAD
Average EV/EBIT: 25.2
Negative Multiple: -1.1 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -191 955.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.5
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.8
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
15.1
13%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.7
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -566.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.2
23%
0.7
AU
CSL Ltd
ASX:CSL
16.8
11%
1.5
NL
argenx SE
XBRU:ARGX
60.1
N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.2 N/A N/A

See Also

Summary
CYAD intrinsic value, competitors valuation, and company profile.
DCF Valuation
CYAD stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CYAD stock valuation using valuation multiples.
Wall Street Estimates
CYAD price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CYAD stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 314,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.